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One-sentence summary: Contrary to previous reports, wild-type p53 can interact with p73 to promote 
cell stress–induced apoptosis. 
Editor’s summary: 
Another look at p53-p73 interactions 
The transcription factor p53 critically regulates cell survival or death in response to cellular stress. 
Mutations in p53 are common in cancer and alter its interactions with other proteins and, consequently, 
with cell fate–specific genes. Mutant p53 binds to and inhibits its family member p73, thereby promoting 
cell survival instead of cell death in response to cell stress. It was believed that this interaction with p73 
was specific to mutant p53. However, Wolf et al. found that wild-type p53 can bind p73 to promote 
stress-induced cell death. Phosphorylation of wild-type p53 by the cell stress–responsive kinase JNK 
caused a conformational change that mirrored the regional structure of the mutant and enabled its binding 
to p73 but, unlike mutant p53, the wild-type protein could still bind to apoptotic gene targets. These 
findings refine our understanding of p53 interactions and specifically p53-p73 coordination in the cell 
stress response. 
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Abstract 
The transcription factors p53 and p73 are critical to the induction of apoptotic cell death, particularly in 
response to cell stress that activates c-Jun N-terminal kinase (JNK). Mutations in the DNA-binding 
domain of p53, which are commonly seen in cancers, result in conformational changes that enable p53 to 
interact with and inhibit p73, thereby suppressing apoptosis. In contrast, wild-type p53 reportedly does 
not interact with p73. Here, we found that JNK-mediated phosphorylation of Thr81 in the proline-rich 
domain (PRD) of p53 enabled wild-type p53, as well as mutant p53, to form a complex with p73. 
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Structural algorithms predicted that phosphorylation of Thr81 exposes the DNA-binding domain in p53 to 
enable its binding to p73. The dimerization of wild-type p53 with p73 facilitated the expression of 
apoptotic target genes [such as those encoding p53-upregulated modulator of apoptosis (PUMA) and Bcl-
2-associated X protein (BAX)] and, subsequently, the induction of apoptosis in response to JNK 
activation by cell stress in various cells. Thus, JNK phosphorylation of mutant and wild-type p53 
promotes the formation of a p53/p73 complex that determines cell fate: apoptosis in the context of wild-
type p53 or cell survival in the context of the mutant. These findings refine our current understanding of 
both the mechanistic links between p53 and p73 and the functional role for Thr81 phosphorylation. 
 
Introduction 
The transcription factor family comprising p53, p63, and p73 are critical regulators of cell fate, 
specifically through the induction of apoptotic cell death in response to cellular stress and developmental 
cues. The three proteins have distinct as well as overlapping and interdependent functions. Mutations in 
p53 are common in human tumors; gain-of-function p53 mutants have a dominant-negative effect on 
wild-type p73 by binding it and inhibiting its ability to bind DNA and thereby preventing its 
transcriptional induction of apoptotic gene (1, 2).  In mice, knockout of one or both alleles of the 
individual genes encoding p53, p63, or p73 resulted in reduced cell death in response to DNA-damaging 
stimuli (3), indicating that all three proteins are necessary to invoke a robust apoptotic response in that 
context. However, whereas wild-type p63 and p73 form heterodimeric (or higher order) complexes, wild-
type p53 reportedly does not (4, 5).   
  Wild-type p53 has two transactivation domains: TAD1 (amino acids 1-40) and TAD2 (amino 
acids 43-54). TAD2 is located proximal to the proline-rich domain (PRD; amino acids 63-97) (6, 7), and 
both TAD2 and the PRD are critical for p53’s induction of apoptotic genes (8, 9), whereas TAD1 is 
reportedly dispensable for this function (10).  Thr81 is a key phosphorylation site within the PRD, as is 
Ser46 within TAD2 (11-15). Several kinases reportedly phosphorylate Ser46 (13, 16, 17), and c-Jun N-
terminal kinase (JNK) phosphorylates Thr81 (18), yet precisely how modification of Thr81 regulates p53 
activity in the context of apoptosis induction is limited.  
 The PRD is an important structural domain; prolyl isomerization in this domain regulates the 
structure of other domains of p53 (19). Additionally, the PRD is necessary for growth suppression and 
apoptosis (20, 21). We rationalized that phosphorylation within this domain may also be sufficient to alter 
the structure of other domains in p53 and thereby regulate its functional interactions. Our findings support 
previously published work on genetic knockout mice, the PRD, and mutant p53/p73 complex formation 
(1, 2) but refine our current understanding of the interaction between wild-type p53 and p73. 
Results  
The phosphorylation of p53 by JNK results in the induction of apoptotic protein PUMA 
Because JNK is a key inducer of p53-mediated apoptosis, and JNK phosphorylates p53 at Thr81, 
we were first curious whether Thr81 was phosphorylated in mutant p53 in cells. In MDA-MB-468 cells, 
which have a missense mutation in p53 (R273HR273X), TMD231 cells, which have a  missense mutation in 
p53 (R280KX), and MDA-MB-157 cells, which have a truncation mutation in p53 (A88fs*52)  , JNK was 
activated, as determined by immunoblotting with antibodies against phospho-Tyr183/Tyr185 JNK (Fig. 1A).  
In addition, mutant p53 was phosphorylated at Thr81 in cells cultured in growth-supporting conditions. 
Treatment with the DNA topoisomerase inhibitor camptothecin or the protein synthesis inhibitor 
anisomycin increased phosphorylation of JNK and phos-Thr81. In various cells that have wild-type p53, 
namely untransformed cell lines NIH3T3 (mouse fibroblast) and HME1 (human mammary epithelial), as 
well as human foreskin fibroblast BJ cells and glioblastoma cell lines U87 and SF767, exhibited limited 
activation of JNK and phosphorylation of p53-Thr81 under growth conditions, but robust induction of both 
upon camptothecin or anisomycin exposure (Fig. 1B and fig. S1). Thus in “normal” cells and tumor cells, 
JNK is activated and p53 (wild-type or mutant) is phosphorylated at Thr81 in response to cell stress.  
We then examined the dependence of JNK activation on the induction of PUMA, the apoptotic 
downstream target of p53. PUMA abundance was increased by anisomycin treatment in cells that had 
wild-type p53 (Fig. 1C), but this induction was blocked by pretreatment with the small molecule JNK 
inhibitor SP600125, thereby confirming that activation of JNK was important for induction of the p53 
target PUMA. Alongside this increase in PUMA abundance was a significant increase in cell death, 
thereby confirming the functional outcome of the pathway (fig. S2). 
The predicted structure of a Thr81 phosphomimic shows a potential mode of binding to p73 
 To gain insight into the structural implications of phosphorylation at Thr81 of p53, we took 
advantage of a protein structure prediction algorithm, I-TASSER (Iterative Threading ASSEmbly 
Refinement) (22-24). Using I-TASSER, we generated predicted protein structure models for wild-type 
p53, R248W mutant p53 (a common DNA binding domain mutant), and a Thr81 phosphomimic p53 
(T81E) (Fig. 2, and data files S1-S5). Analysis of wild-type and mutant p53 showed distinct structural 
differences in the amino and carboxy termini. The Thr81 phosphomimic mutation (T81E) substantially 
changed the structure of the tetramerization/regulatory (TET/REG) domain compared to that of the 
unphosphorylated wild-type p53. The TET/REG domain of the T81E model more closely resembled the 
R248W mutant p53 model than the wild-type p53 model. The R248W mutation of p53 is one of the 
mutants that binds to p73 (1). It is probable that it is this structural change in the TET/REG domain that 
enables p53 to interact with p73, which explains the original finding that wild-type p53 was unable to 
bind to p73. The results of our structural analysis implies that phosphorylation at Thr81 of p53 is 
permissive of binding to p73. We also produced in silico structural models of the S46D phosphomimic 
p53 and a R248W/T81E mutant p53 phosphomimic (Fig. 2) to examine if there were any structural 
changes in these constructs. The TAD2 of the S46D phosphomimic was structurally similar to the T81E 
phosphomimic but distinct from either of the R248W mutant p53 models. Given that phosphorylation at 
Ser46 of p53 is needed for a robust apoptotic response, and phosphorylation at Thr81 of p53 causes a 
structural change similar to that of phosphorylation at Ser46, these data suggest that TAD2 and PRD are 
integrated into important structural changes that are associated with induction of apoptotic genes.  
Compared to mutant p53 alone (R248W), the Thr81 phosphomimic of R248W mutant p53 (R248W/T81E) 
causes an additional structural change in almost every single functional domain. This finding would 
suggest that the use of a JNK inhibitor may reduce the binding of mutant p53 to p73 without completely 
ablating the interaction. 
Phosphorylation of Thr81 of p53 promotes a p53-p73 complex 
Our structural data (Fig. 2) combined with previous reports that mutant p53 binds wild-type p73 
and the observation of high basal Thr81 phosphorylation of mutant p53 (Fig.1) led us to examine whether 
blocking JNK with the selective small-molecule inhibitor SP600125 could alter the mutant p53-p73 
interaction endogenously. Mutant p53 was immunoprecipitated from lysates from TMD231 cells treated 
with DMSO or SP600125 and blotted for coincident pulldown of p73.  We found that p73 co-purified 
with mutant p53 and that this binding was decreased by 40% when JNK activity was blocked with 
SP600125 (Fig. 3A). This data suggests that JNK has only a modest effect on the interaction between 
mutant p53 and p73, which was predicted in the structural data (Fig.2). We next tested whether wild-type 
p53 and p73 were affected by JNK-mediated phosphorylation. To do this, we transiently transfected 
H1299 cells with wild-type p53 and HA-tagged p73, then treated the transfected cells with DMSO or 
anisomycin.  Immunoprecipitation of wild-type p53 from cellular extracts shows that p73 co-purified only 
when JNK was activated with anisomycin (Fig. 3B). To provide evidence that phosphorylation of Thr81 
was necessary for wild-type p53 to co-purify with p73, we transiently transfected H1299 cells with wild-
type p53 or the T81E phosphomimic. Immunoprecipitation of exogenous p53 revealed that T81E, but not 
wild-type p53, co-purified with endogenous p73 (Fig. 3C) Likewise, immunoprecipitation of endogenous 
p73 from extracts from U87 cells treated with DMSO, anisomycin, SP600125, or pretreated with 
SP600125 before anisomycin showed that endogenous wild-type p53 co-purifed with p73 only when 
Thr81 was phosphorylated (Fig. 3D).  These data substantially suggest that Thr81 phosphorylation in p53 is 
critical for the formation of a wild-type p53-p73 complex. To definitively show this, we used various p53 
phosphomimics (T81E, S46D, T81E-S46D) and p73 produced in bacteria and performed Far-Western 
analysis to examine the requirement of Thr81 phosphorylation. We fixed recombinant wild-type p53, the 
phosphomimics, and two positive controls (MDM2 and MDMX) to nitrocellulose, then incubated the 
membrane with recombinant p73 and blotted for p73. In support of our cellular data presented above, this 
in vitro approach confirmed that p73 bound only to T81E and not wild-type p53 or S46D p53 (Fig. 3E). 
We also probed for p53 in a separate lane to show the relative amounts of p53 loaded per well (Fig. 3E).  
Collectively, through overexpression, endogenous and recombinant approaches, we conclude that p73 
will bind to wild-type p53 when p53 is phosphorylated at Thr81.  
 To gain insight into where p53 and p73 interact, we performed confocal immunofluorescence 
microscopy analysis on MDA157, HME, or TMD231 cells grown on coverslips and treated with 
anisomycin, SP600125, or DMSO. Anisomycin treatment caused a significant increase in colocalization 
between p53 and p73 in the nucleus of p53–wild-type HME cells but not p53-mutant MDA157 cells (Fig. 
4, A and B; table S1).  Blocking JNK activity with SP600125 in TMD231 cells, which have mutant p53 
and high basal activation of JNK, caused a significant decrease in the colocalization of mutant p53 and 
p73 in the nucleus (Fig. 4C and table S1), which is in accordance with the decrease in binding of mutant 
p53 and p73 (Fig. 3). To ensure that anisomycin was indeed activating JNK and increasing 
phosphorylation at Thr81, and that SP600125 was inhibiting JNK and decreasing phosphorylation at Thr81 
of p53, the same cells were treated as described in the confocal experiments and lysates were Western 
blotted for active JNK and phosphorylated Thr81 p53 (fig. S3).  
The JNK-initiated p53-p73 pathway is important for apoptosis 
Above, we showed that phosphorylation of Thr81 of p53 resulted in its interaction with p73 (Fig. 
3) and an increased abundance of PUMA (Fig. 1C).  Therefore, we examined whether p53, p73, and JNK 
activation was necessary for the induction of apoptosis. We showed that the removal of p53 in p53–wild-
type BJ cells resulted in resistance to JNK-activated cell death by anisomycin treatment (Fig. 5A). 
Specifically, treatment with anisomycin for 9 hours initiated a steady increase in the abundance of BAX 
and PUMA, which was prevented by shRNA-mediated knockdown of p53. In contrast, the abundance of 
BAX increased after 6 hours of anisomycin treatment; this may be due to the cells overcoming the 
shRNA knockdown at 6 hours in response to prolonged anisomycin-induced stress (Fig. 5A).  
The apoptotic resistance conferred to BJ cells transfected with p53-shRNA was further 
investigated using a methylene-blue cell death assay (Fig. 5B) and by assessing cell number as a factor of 
green fluorescent protein (GFP) (shRNA vector) signal (Fig. 5C). Loss of p53 improved cell viability 
through anisomycin treatment (Fig. 5, B and C), suggesting that the lack of the p53-p73 complex results 
in resistance to apoptosis. To test the impact of specifically Thr81 phosphorylation on cell death, we co-
expressed GFP and either wild-type p53 or a p53 mutant that cannot be phosphorylated at Thr81 (T81A)   
in H1299 cells and examined survival after anisomycin treatment by GFP fluorescence. The data revealed 
an increase in survival in cells expressing T81A point mutation compared to wild-type p53 (Fig. 5D), 
confirming previously published observations with this mutant (18) and that Thr81 phosphorylation in p53 
is critical to cell stress-induced apoptosis. 
 
Discussion  
The tumor suppressor p53 is highly studied given its role in regulating many cellular activities 
and responses, including cell cycle arrest, DNA repair, cell death, and metabolism. Its family member p73 
has some described overlapping functions; yet, unlike p53, p73 is rarely mutated in human cancer. While 
p73 is rarely mutated, mutation of p53 may function as a dominant negative to ablate p73 activity (1). The 
regulation of p53 is extremely important given that its differential regulation can dictate distinct binding 
partners and, consequently, distinct outcomes through transcriptional targets, such PTEN to promote 
apoptosis versus MDM2 to promote re-entry into the cell cycle and survival (25, 26). Increased abundance 
of PTEN, a protein/lipid phosphatase that inhibits the PI3K (phosphatidylinositol 3-kinase)–AKT (protein 
kinase B) pathway, can protect p53 from MDM2-mediated degradation induced by AKT (11, 27-30). 
Thus, p53 can selectively induce PTEN expression and programmed cell death instead of the 
autoregulatory feedback loop with MDM2 to promote cell survival (11, 31). Moreover, PTEN can form a 
complex with p73 and bind to the PUMA promoter to increase its expression, leading to the induction of 
apoptosis (32). These molecular and biochemical studies are supported by genetic studies in mice where 
the loss of p53, p73, or PTEN confers resistance to apoptotic stimuli and an increase in neoplastic 
development (3, 33-36).  Thus, an effective response to apoptotic stimuli requires the integration of 
numerous intact tumor suppressors, yet how these tumor suppressors are signaled to form a complex has 
not previously been clearly defined.  
 There are well-characterized kinase signaling pathways that phosphorylate p53 and p73 in 
response to DNA damage, but some phosphorylation sites appear to be dispensable for the induction of 
apoptosis. It has been reported by several groups that Ser46 and Thr81 are important for the induction of 
apoptosis (11, 13, 15, 17). Homeodomain-interacting protein kinase 2 (HIPK2) and the mitogen-activated 
protein kinase p38 reportedly phosphorylate Ser46 of p53, whereas JNK, which plays dual roles in cellular 
proliferation and cell death (37), phosphorylates Thr81 of p53 (11, 13, 15, 17). One of JNK’s substrates is 
p73, which mediates JNK-induced apoptosis (38), but it was unclear how. Analysis of apoptosis by the 
JNK-p73 axis in that previous study (38) was performed in cells that maintained expression of wild-type 
p53, and notably, p53 abundance does not directly correlate with its activity; for example, neddylation of 
p53 in response to growth factor signaling renders p53 stable but inactive (39).  Untransformed cell lines  
have an intact apoptotic pathway and deneddylating enzymes, tumor suppressors, active kinases, and 
post-translational modification enzymes that are activated in response to genotoxic stress that provide a 
robust induction of apoptosis.     
There is renewed interest in p53 family member interactions, and several studies have highlighted 
the importance of the interactions between different family members (40-42). Our studies have linked the 
JNK-p53-p73 proteins showing that phosphorylation of p53 at Thr81 by JNK is permissive of a p53-p73 
interaction. Notably, our structural modeling analysis revealed that the structure of phosphorylated Thr81 
is nearly identical to that of R248W. Therefore, activated JNK can convert wild-type p53 to mimic mutant 
p53 with regards to binding to p73 by exposing the DNA binding domain.  Ser46 is proximal to the proline 
rich domain in the second transactivation domain, which may be important for additional structural 
changes to recruit other factors for gene expression.  However, we also found that phosphorylation of 
Ser46 has no effect on binding to p73, supporting that this phosphorylation may instead be required for 
recruiting additional coactivators.  The JNK-mediated interaction between wild-type p53 and p73 
provides biochemical evidence in support of the existing animal models and gene dose sensitivity of p53 
and p73 to apoptosis (33). We also show that in mutant p53 cells, JNK activity is increased resulting in a 
mutant p53/wild-type p73 complex with mutant p53 acting as a dominant negative partner of p73. These 
data are consistent with previous reports showing that mutant p53/p73 form a complex (2). This complex 
mediates apoptosis in cells that express wild-type p53, but survival in cells that express mutant p53. Thus, 
our findings refine our understanding of how cells promote, or in certain contexts circumvent, the p53 
apoptotic signaling axis.  
 
Materials and Methods 
 
Cell culture and transfection.  H1299, TMD231, U87, HME1, SF767, 3T3, hTert BJ, MDA-MB-468 and 
MDA-MB-157 were cultured in Dulbecco’s Modified Eagle Media (DMEM) with 10% fetal bovine 
serum (FBS) supplemented with penicillin and streptomycin at 370 C humidified incubator in 5% CO2.  
Anisomycin, SP600125, and Camptothecin were purchased and suspended as described by the 
manufacturer (Sigma-Aldrich). Anisomycin was used at 30 µM, Camptothecin was used at 30 µM, and 
SP600125 was used at 25 µM unless otherwise noted. Transient transfections were performed using 
lipofectamine per manufacturer’s instructions (Life Technologies).  Annexin V cell dead kit from 
Millipore was used to stain cells which were analyzed on a MUSE cytometer.   
 
Plasmids, protein purification, and Western blotting. We generated mutant p53 at Thr81 with a site 
directed mutagenesis kit (Life technologies). Recombinant p73 and p53 proteins were produced in 
BL21DE3 cells and purified as previously described (30, 32).  Far-Western was completed by 96-well dot 
blot system and recombinant proteins were placed in wells and fixed to nitrocellulose by drying.  Blot 
was blocked with 5% nonfat dry milk and incubated with recombinant p73. p73 was then detected by p73 
antibody followed by secondary and an enhanced chemiluminescence (ECL) reagent.  Western blot 
analysis used whole cell lysates lysed under denaturing conditions (6 M urea buffer) or 
immunoprecipitated proteins extracted with lysis buffer, as described previously (32).  Antibody for p73 
(OP1008) was purchased from Millipore; antibodies for phos-T81, phos-Y183/Y185 JNK, and PUMA 
were purchased from Cell Signaling Technology; and antibodies for p53 (D0-1), actin, and GAPDH were 
purchased from Santa Cruz Biotechnology.  
 
I-TASSER protein structure prediction. Amino acid sequences for wild-type p53, R248W p53, T81E p53, 
S46D, and R248W/T81E p53 were input to the I-TASSER web server as FASTA sequences. Predicted 
protein structures were generated using a previously described method (22-24) and analyzed using the 
CCP4 Molecular Graphics Program (CCP4MG) v. 2.10.6 (43). Structures were superposed using a built-
in function within the software. 
 
Immunofluorescence microscopy. MDA157, HME, or TMD231 cells were grown on glass coverslips and 
fixed in 4% paraformaldehyde in phospho-buffered saline (PBS) for 15 minutes, washed with PBS, and 
permeabilized in 1% Triton X-100 in PBS for 15 minutes. Coverslips were blocked in 5% bovine serum 
albumin for 1 hour in PBS/Tween before being stained with p73 (D3G10, rabbit monoclonal, Cell 
Signaling Technologies) and p53 (DO-1, mouse monoclonal, Santa Cruz) antibodies. Coverslips were 
then incubated with anti-rabbit AlexaFluor 647 and anti-mouse AlexaFluor 488 secondary antibodies 
before being fixed to slides with ProLong Diamond Antifade Mountant with DAPI (Life Technologies). 
Slides were visualized on a Leica SP8 MP microscope. Colocolization analysis was performed using 
Imaris v9.0.2, and colocalized images were created using the “RG2B_Colocolization” plugin for ImageJ. 
Scale bar, 25 µm (MDA157, TMD231) or 50 µm (HME). 
 Colony forming assay. Empty vector- or shp53-transduced hTert BJ cells where plated in triplicate and 
treated with anisomycin for 9 hours. Dimethyl sulfoxide (DMSO) was used as a vehicle control. Cells 
were stained with equal parts methanol and methylene blue for 15 min. The plate was then washed 3 
times with deionized water to remove any excess stain and left to dry at room temperature. 
 
GFP florescence assay. BJ cells expressing green fluorescent protein (GFP) TP53 shRNA (shp53) or 
empty (control) pLVTHM vector (XXXX) were plated in quadruplet and treated with DMSO or 
anisomycin (10 μM) for 48 hours. Fluorescence emitted by GFP in each well was measured at 509 nm 
using a SpectraMax M5 spectrophotometer (Molecular Devices).  
 
Statistical analysis. Data were analyzed by two-tailed unpaired t tests. P values <0.05 were considered 
significant. 
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Figure Legends:  
Fig. 1. Phosphorylation of Thr81 of p53 in response to JNK activation. (A) Western blot of 
phosphorylated JNK, phosphorylated Thr81 of p53, and actin in cellular extracts from TMD231, MDA-
MB-468 and MDA-MB-157 cells treated with either camptothecin or anisomycin for the indicated times. 
Blots are representative of three independent experiments. (B) Western Blot of phosphorylated JNK or 
Thr81 of p53 and actin from cellular extracts from 3T3, SF767, HME-1, BJ and U87 treated with 
anisomycin or camptothecin for the indicated times. Blots are representative of three independent 
experiments (quantified in fig. S1). (C) U87 or SF767 cellular extracts from DMSO, SP600125, 
anisomycin or pretreatment with SP600125 then anisomycin, and western blotted for PUMA and actin. 
Blots are representative of two independent experiments. 
 
Fig. 2. Predicted structure for a Thr81 phosphomimic reveals a possible mode of binding to p73. (A 
and B) Structures (A) and amino acid coverage (B) of domains in wild-type and mutant p53. Whole 
protein represents amino acids 1-393 of p53. Transactivation domains 1 and 2 (TAD1/TAD2) represent 
amino acids 1-40 and 43-54. The proline rich domain (PRD) represents amino acids 63-97. The 
tetramerization and regulatory domains (TET/REG) represent amino acids 323-393. T81, Thr81; E, 
glutamic acid in T81E phosphomimic mutant domain. Arrows in the TET/REG domain structures 
indicate the region of a conformational change that is permissive of binding.  
 
Fig. 3. Formation and activity of a p53-p73 complex.  (A) Immunoprecipitiation of p53 or control IgG 
from TMD231 cells treated with DMSO or SP600125 and western blotted for p73 and p53. Blots are 
representative of four independent experiments. (B) Transient transfection of H1299 cells with p53, HA-
p73 and treated with either DMSO or Anisomycin. Western blot of p53 and HA from p53 
immunoprecipitated from cellular extracts. Blots are representative of two independent experiments. (C)  
Immunoprecipitiation of p53 or control IgG and western blot of p53 and p73 from H1299 cells transfected 
with wild type p53 or T81Ep53. WCL is whole cell lysate from H1299 cells. Blots are representative of 
two independent experiments. (D) Immunoprecipitation of endogenous p73 from U87 cells treated with 
SP600125, anisomycin or both and western blot of phospho-Thr81, p53, and p73. Blots are representative 
of two independent experiments. (E) Far-Western analysis of p73 binding to p53.  Lane 1 corresponds to 
p53 and the phosphomimics of p53; lane 2 is MDM2 and MDMX. Right, blotting for p73 to detect 
binding to p53, MDM2, and MDMX (right panel).  Left, the relative amount of p53 on the membrane. 
Blots are representative of two independent experiments. 
 
Fig. 4. Colocalization of p53 with p73. (A to C) Immunofluorescence assessing nuclear colocalization 
of p53 (green) and p73 (red) in MDA157 cells (A) and HME cells (B) treated with anisomycin (Aniso) or 
DMSO and in TMD231 cells (C) treated with SP600125 or DMSO. Arrows indicate the cell magnified in 
inset (bottom right) of each image. Scale bars, 25 µm (MDA157, TMD231) or 50 µm (HME). Data are 
mean ± S.E. from three independent experiments; P determined by two-tailed unpaired t test. 
 
Fig. 5. Downstream effects of the p53-p73 pathway. (A) Western blot of BAX, PUMA, and p53 in 
cellular extracts from BJ cells transfected with empty vector control (E.V.) or p53-shRNA (shp53) and 
treated with anisomycin for the indicated time. Blots are representative of three independent experiments; 
E.V. and shp53 samples were developed on the same membrane. (B) Methylene Blue staining cell 
viability assay in E.V.- and shp53-transfected BJ cells treated with DMSO or anisomycin for 9 hours. 
Data is representative of three independent experiments. (C) Relative GFP fluorescence was measured in 
GFP shp53 and LVTHM empty vector BJ cells. Cells were treated with DMSO or anisomycin for 48 
hours. Relative fluorescence was derived from DMSO controls. Data is representative of four independent 
experiments. Significance was determined by a two-tailed unpaired t test (***P<0.005) (D) Green 
fluorescence was measured in H1299 cells transfected with GFP alone or GFP and either wild-type or 
T81A p53, then treated with DMSO or anisomycin. Fold change survival was calculated as the change in 
survival of anisomycin-treated cells relative to DMSO-treated cells, and normalized to the GFP-alone 
control. Data are mean ± S.E. from three independent experiments.  
 
Fig. 6. Cell fate is dictated by formation of a p53-p73 complex. Schematic of our model. 
Apoptotic stimuli, for example DNA damage, results in the phosphorylation and activation of 
JNK. JNK phosphorylates wild-type p53 (green hexagons) at Thr81 causing a structural change in 
p53 and the subsequent binding of p73 (red diamonds). This complex drives the transcription of 
PUMA and BAX, leading to apoptosis. Mutant p53 (blue hexagons) does not require 
phosphorylation by JNK to form a complex with p73. Phosphorylation of mutant p53 instead 
serves to enhance p53 binding with p73, hence increasing total complex formation. However, 
because of the dysfunctional DNA binding domain in mutant p53 as well as its sequestering of 
p73 by complex formation, PUMA and BAX are not transcribed, thus decreasing the apoptotic 
signal and promoting tumor cell survival.  
 
 
Figure S1. Activation of pT81 in WT p53 cell lines. Densitometry of pT81 p53 from three 
independent experiments plotted as the mean of the fold change +/- standard deviation.  
 
 
Figure S2. U87 cell death. U87 cells were treated with 30 µM camptothecin for 6 hours or 
pretreated with 25 µM SP600125 for one hour and then treated with 30 µM camptothecin for 6 
hours. Cell death was determined by flow cytometry using Annexin V. Error bars represent 
standard deviation from the mean; P values determined by a two-tailed unpaired t-test. 
 
 
 
 
 
Figure S3.  JNK activation or inhibition in HME, MDA157, and TMD231 cell lines. Western 
blotting for activated JNK (p-JNK) and phosphorylated p53 (at Thr81; p-p53) in whole-cell lysates 
from HME and MDA157 cells treated with 30 µM anisomycin or DMSO for 6 hours and TMD231 
cells treated with 25 µM SP600125 or DMSO for 6 hours. 
  
 
 
  A = p73, B = p53 Manders’ A Standard Error Manders’ B Standard Error 
MDA157 
DMSO (n = 109) 0.468 0.021 0.389 0.021 
Anisomycin (n = 61) 0.458 0.023 0.448 0.018 
Significance (p value) 0.763   0.060   
TMD231 
DMSO (n = 53) 0.353 0.020 0.404 0.018 
SP600125 (n= 49) 0.114 0.012 0.398 0.009 
Significance (p value) 7.84E-17   0.765   
HME 
DMSO (n = 72) 0.519 0.006 0.281 0.017 
Anisomycin (n = 67) 0.560 0.011 0.371 0.024 
Significance (p value) 0.001   0.002   
 
Table S1. Manders’ Coefficients for microscopy colocalization analysis. Mander’s A and B 
coefficients were generated using p73 as channel A and p53 as channel B within the Imaris 
software. Significance was determined using a two-tailed unpaired t test. 
 
  
Data File S1. Wild-type p53 structure (PDB). Structure obtained from the I-TASSER software 
using the FASTA protein sequence for p53. NCBI Reference Sequence: NP_000537.3. Note: 3D 
Protein structure .pdb files require special software to view them. There is a web-based 3D structure 
viewer sponsored by NCBI (https://www.ncbi.nlm.nih.gov/guide/howto/view-3d-struct-prot/) that allows 
the user to upload and view .pdb files. 
 
Data File S2. p53 R248W structure (PDB). Structure obtained from the I-TASSER software 
using the NCBI protein sequence for p53, with the addition of the R248W mutation. Note: 3D 
Protein structure .pdb files require special software to view them. There is a web-based 3D structure 
viewer sponsored by NCBI (https://www.ncbi.nlm.nih.gov/guide/howto/view-3d-struct-prot/) that allows 
the user to upload and view .pdb files. 
 
Data File S3. p53 T81E structure (PDB). Structure obtained from the I-TASSER software using 
the NCBI protein sequence for p53, with the addition of the T81E mutation. Note: 3D Protein 
structure .pdb files require special software to view them. There is a web-based 3D structure viewer 
sponsored by NCBI (https://www.ncbi.nlm.nih.gov/guide/howto/view-3d-struct-prot/) that allows the 
user to upload and view .pdb files. 
 
Data File S4. p53 S46D structure (PDB). Structure obtained from the I-TASSER software using 
the NCBI protein sequence for p53, with the addition of the S46D mutation. Note: 3D Protein 
structure .pdb files require special software to view them. There is a web-based 3D structure viewer 
sponsored by NCBI (https://www.ncbi.nlm.nih.gov/guide/howto/view-3d-struct-prot/) that allows the 
user to upload and view .pdb files. 
 
Data File S5. p53 R248W/T81E structure (PDB). Structure obtained from the I-TASSER 
software using the NCBI protein sequence for p53, with the addition of both the R248W and the 
T81E mutations. Note: 3D Protein structure .pdb files require special software to view them. There is a 
web-based 3D structure viewer sponsored by NCBI (https://www.ncbi.nlm.nih.gov/guide/howto/view-
3d-struct-prot/) that allows the user to upload and view .pdb files. 






